Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Breast 2Tumor-Agnostic 1Head & Neck 1Endocrine 1

Conditions

Heart Failure 2Breast Neoplasms 2Neoplasms, Second Primary 1Cardiotoxicity 1Breast Diseases 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 467Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × sacubitril and valsartan sodium hydrate drug combination × Breast × Clear all
NCT05465031 2025-03-14

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Silesian Centre for Heart Diseases

Phase 4 Recruiting
600 enrolled
Breast

Breast Diseases, Breast Neoplasms, Heart Failure, Neoplasms, Second Primary, Cardiotoxicity

NCT03760588 2025-02-12

PRADAII

University Hospital, Akershus

Phase 2 Completed
138 enrolled
Breast

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡